Tigris Pharmaceuticals Presents Results Of Breast Cancer Research At AACR Annual Meet
 

Tigris Pharmaceuticals, Inc., a privately held drug development company, announced that preclinical data were presented on its novel molecule, AFP-464, during the recent AACR 100th Annual Meeting 2009 in Denver. "This research represents a significant advancement in the treatment of Triple Negative Breast Cancer, one of the most aggressive forms of invasive breast cancer," stated Edmundo Muniz, M.D., Ph.D., President and Chief Executive Officer of Tigris.

More...